INSTITUT CARNOT CALYM

LYMPHOMA BIOMARKERS RESEARCH & DEVELOPMENT OFFER

In order to improve diagnosis, guide therapy decisions and/or predict tumor responses, CALYM researchers develop new lymphoma biomarkers (tissue, blood, imaging) in collaboration with industry.

According to its partners' needs, CALYM offers to carry out the research and co-development of lymphoma biomarkers in this way:

CALYM (and possibly its industrial partners):
- carries out the biomarker discovery phase and establishes the proof of concept
- transfers the biomarker/the technology
- carries out the clinical validation phase

CALYM's partner (*in vitro* diagnosis, biotechnology, pharmaceutical company)
- products and qualifies analytically the assay (kit)
- obtains the CE marking authorization
- carries out the commercialization and distribution phase



CONTACT US!
partnering@calym.org - +33 4 72 66 93 33
www.calym.org

INSTITUT CARNOT
CALYM

LYMPHOMA BIOMARKERS RESEARCH & DEVELOPMENT OFFER

In order to improve diagnosis, guide therapy decisions and/or predict tumor responses, CALYM researchers develop new lymphoma biomarkers (tissue, blood, imaging) in collaboration with industry.

CALYM EXPERTISE

- Discovery of new lymphoma biomarkers (diagnosis, prognosis, pharmacodynamics, clinical response predictive, surrogate, safety…)
- Clinical validation in large cohorts and registration as part of a clinical trial
- Assay development for the clinical setting (e.g. from oriented genome-wide technologies to routine technologies such as RT-MLPA)

CALYM RESOURCES & MEANS

- Access to data
  - All types: genomic, transcriptomic, immunohistochemistry, imaging, clinical, etc.
- Sources
  - Pre-existing CALYM datasets
  - Profiles of samples from the CALYM clinically annotated biological collections
  - De novo sample collection as part of clinical trials
  - Data from CALYM pre-clinical models (cell lines, mice…)
- Analytical expertise (bioinformatics & biostatistics)
  - Screening, feature selection and model construction (gene signatures, IHC algorithm…) from training set
  - Validation in independent dataset



KEY FIGURES

- **CEVI COLLECTION: 700+ SAMPLES OF HUMAN VIABLE CELLS FROM LYMPHOMAS AND REACTIVE TISSUES**
- **TENOMIC COLLECTION: CLINICALLY ANNOTATED SAMPLES OF T-CELL LYMPHOMA FROM 900+ PATIENTS**
- **CLINICALLY ANNOTATED PROPRIETARY DATABASE OF 23,000+ LYMPHOMA PATIENTS**
- **IMAGING PROPRIETARY DATABASE OF 18,000+ EXAMINATIONS**

CONTACT US!
partnering@calym.org - +33 4 72 66 93 33
www.calym.org